AngioDynamics Financials

Name: AngioDynamics reports earnings 30th of March 2023
Start: 2023-03-30
End: 2023-03-30
Location: AngioDynamics

ANGO Stock

USD 12.07 0.22 1.79%

AngioDynamics Working Capital is very stable at the moment as compared to the past year. AngioDynamics reported last year Working Capital of 79.37 Million.

With this module, you can analyze AngioDynamics financials for your investing period. You should be able to track the changes in AngioDynamics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

AngioDynamics Most Recent Estimates

Diluted Eps

(0.84)

EPS Estimate Current Year

(0.01)

EPS Estimate Next Year

0.11

EPS Estimate Current Quarter

(0.01)

Earnings Share

(0.84)

Understanding current and past AngioDynamics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AngioDynamics' financial statements are interrelated, with each one affecting the others. For example, an increase in AngioDynamics' assets may result in an increase in income on the income statement.

The financial analysis of AngioDynamics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for AngioDynamics includes many different criteria found on its balance sheet. For example, investors should never minimize AngioDynamics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor AngioDynamics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in AngioDynamics.

Cash and Equivalents

48.65 Million

Evaluating AngioDynamics' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of AngioDynamics' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the AngioDynamics' relative financial performance

Chance Of Distress

Less than 3

AngioDynamics has less than 3 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for AngioDynamics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.

Please note, AngioDynamics' odds of distress score SHOULD NOT be confused with the real chance of AngioDynamics filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as AngioDynamics is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include AngioDynamics' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

The data published in AngioDynamics' official financial statements usually reflect AngioDynamics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AngioDynamics. For example, before you start analyzing numbers published by AngioDynamics accountants, it's critical to develop an understanding of what AngioDynamics' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.

Please note, the presentation of AngioDynamics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AngioDynamics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AngioDynamics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AngioDynamics. Please utilize our Beneish M Score to check the likelihood of AngioDynamics' management to manipulate its earnings.

AngioDynamics Company Summary

AngioDynamics competes with Good Times, Alaska Air, Pebblebrook Hotel, Playa Hotels, and Red Rock. AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access and for use in oncology and surgical settings in the United States and internationally. The company was founded in 1988 and is headquartered in Latham, New York. Angiodynamics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 760 people.

Specialization	Health Care, Health Care Equipment & Services
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
CIK Number	0001275187
ISIN	US03475V1017
CUSIP	03475V101
Region	North America
Location	New York; U.S.A
Business Address	14 Plaza Drive,
Sector	Health Care Equipment & Supplies
Industry	Health Care
Benchmark	NYSE Composite
Website	www.angiodynamics.com
Phone	518 795 1400
Currency	USD - US Dollar

You should never invest in AngioDynamics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of AngioDynamics Stock, because this is throwing your money away. Analyzing the key information contained in AngioDynamics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

AngioDynamics Key Financial Ratios

Generally speaking, AngioDynamics' financial ratios allow both analysts and investors to convert raw data from AngioDynamics' financial statements into concise, actionable information that can be used to evaluate the performance of AngioDynamics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that AngioDynamics reports annually and quarterly.

	Return On Asset	(0.0247) %
	Profit Margin	(0.1) %
	Operating Margin	(0.07) %

More Fundamentals

AngioDynamics Key Balance Sheet Accounts

	2018	2019	2020	2021	2022	2023 (projected)
Inventories	40.07 M	59.91 M	48.61 M	51.39 M	46.25 M	45.57 M
Receivables	43.58 M	34.17 M	35.41 M	52.3 M	47.07 M	43.52 M
Accounts Payable	22.83 M	19.1 M	19.63 M	28.05 M	25.24 M	22.12 M
Total Assets	836.44 M	594.21 M	561.44 M	552.75 M	497.48 M	559.2 M
Current Assets	315.29 M	152.91 M	140.88 M	143.34 M	164.85 M	182.74 M
Assets Non Current	521.15 M	441.3 M	420.56 M	409.41 M	368.47 M	421.5 M
Cash and Equivalents	227.64 M	54.44 M	48.16 M	28.82 M	33.15 M	48.65 M
Total Debt	131.91 M	40 M	20 M	25 M	22.5 M	23.09 M
Debt Non Current	124.41 M	40 M	20 M	25 M	22.5 M	23.09 M
Shareholders Equity	614.82 M	454.87 M	439.46 M	424.49 M	382.04 M	416.58 M
Inventory	40.07 M	59.91 M	48.61 M	51.39 M	46.25 M	46.88 M
Total Liabilities	221.62 M	139.34 M	121.98 M	128.26 M	115.44 M	142.63 M
Current Liabilities	73.3 M	51.45 M	57.58 M	74.32 M	85.47 M	81.73 M
Tax Liabilities	14.54 M	24.06 M	19.95 M	16.04 M	18.44 M	18.9 M

AngioDynamics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what AngioDynamics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.

	2018	2019	2020	2021	2022	2023 (projected)
Direct Expenses	114.63 M	113.89 M	134.22 M	150.49 M	135.44 M	130.76 M
Consolidated Income	61.34 M	(166.79 M)	(31.55 M)	(26.55 M)	(23.89 M)	(25.78 M)
Cost of Revenue	114.63 M	113.89 M	134.22 M	150.49 M	135.44 M	131.05 M
Gross Profit	156 M	150.27 M	156.79 M	165.73 M	149.16 M	145.13 M
Interest Expense	5.1 M	907 K	861 K	688 K	619.2 K	635.5 K
Net Income	61.34 M	(166.79 M)	(31.55 M)	(26.55 M)	(23.89 M)	(25.78 M)
Operating Expenses	172.38 M	329.03 M	191.89 M	193.78 M	222.85 M	224.47 M
Operating Income	(16.38 M)	(178.76 M)	(35.1 M)	(28.05 M)	(25.24 M)	(27.24 M)
Revenues	270.63 M	264.16 M	291.01 M	316.22 M	284.6 M	276.19 M
Income Tax Expense	(3.56 M)	(1.35 M)	(4.5 M)	(3.4 M)	(3.06 M)	(3.14 M)

AngioDynamics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of AngioDynamics. It measures of how well AngioDynamics is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money AngioDynamics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money AngioDynamics had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what AngioDynamics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.

	2018	2019	2020	2021	2022	2023 (projected)
Capital Expenditure	(3.12 M)	(7.24 M)	(13.71 M)	(15.71 M)	(14.14 M)	(14.51 M)
Depreciation Amortization and Accretion	25.88 M	25.88 M	28.37 M	31.79 M	36.56 M	34.4 M
Net Cash Flow or Change in Cash and Cash Equivalents	153.54 M	(173.21 M)	(6.27 M)	(19.34 M)	(17.4 M)	(17.86 M)
Issuance Purchase of Equity Shares	2.03 M	(759 K)	3.01 M	2.68 M	2.41 M	2.04 M
Issuance Repayment of Debt Securities	40 M	(92.5 M)	(20 M)	5 M	4.5 M	4.86 M
Net Cash Flow from Financing	33.93 M	(95.24 M)	(16.99 M)	7.68 M	6.91 M	7.46 M
Net Cash Flow from Investing	82.55 M	(63.34 M)	(13.71 M)	(19.31 M)	(22.2 M)	(23.96 M)
Net Cash Flow from Operations	37.44 M	(14.55 M)	24.09 M	(7.19 M)	(6.47 M)	(6.64 M)
Share Based Compensation	9.25 M	7.59 M	8.62 M	10.69 M	12.3 M	10.24 M

AngioDynamics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining AngioDynamics's current stock value. Our valuation model uses many indicators to compare AngioDynamics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AngioDynamics competition to find correlations between indicators driving AngioDynamics's intrinsic value. More Info.

AngioDynamics is number one stock in working capital category among related companies. It is number one stock in cash per share category among related companies . The ratio of Working Capital to Cash per Share for AngioDynamics is about 256,538,710 . AngioDynamics Working Capital is very stable at the moment as compared to the past year. AngioDynamics reported last year Working Capital of 79.37 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value AngioDynamics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AngioDynamics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AngioDynamics' earnings, one of the primary drivers of an investment's value.

AngioDynamics Systematic Risk

AngioDynamics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AngioDynamics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.

The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on AngioDynamics correlated with the market. If Beta is less than 0 AngioDynamics generally moves in the opposite direction as compared to the market. If AngioDynamics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AngioDynamics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AngioDynamics is generally in the same direction as the market. If Beta > 1 AngioDynamics moves generally in the same direction as, but more than the movement of the benchmark.

About AngioDynamics Financials

What exactly are AngioDynamics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include AngioDynamics' income statement, its balance sheet, and the statement of cash flows. Potential AngioDynamics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although AngioDynamics investors may use each financial statement separately, they are all related. The changes in AngioDynamics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AngioDynamics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze AngioDynamics Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as AngioDynamics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of AngioDynamics has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

In summary, you can determine if AngioDynamics' financials are consistent with your investment objective using the following steps:

Review AngioDynamics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand AngioDynamics' liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare AngioDynamics' financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if AngioDynamics' stock is overvalued or undervalued.

Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to conduct additional research and seek professional advice.

AngioDynamics Thematic Clasifications

AngioDynamics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases

Cancer Fighters

View

This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas

AngioDynamics March 23, 2023 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of AngioDynamics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AngioDynamics. We use our internally-developed statistical techniques to arrive at the intrinsic value of AngioDynamics based on widely used predictive technical indicators. In general, we focus on analyzing AngioDynamics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AngioDynamics's daily price indicators and compare them against related drivers.

	Downside Deviation	2.56
	Information Ratio	0.0352
	Maximum Drawdown	21.29
	Value At Risk	(3.96)
	Potential Upside	3.55

Check out Trending Equities. To learn how to invest in AngioDynamics Stock please use our How to Invest in AngioDynamics guide. Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for AngioDynamics Stock analysis

When running AngioDynamics price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.

	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Fund Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Price Transformation Use Price Transformation models to analyze depth of different equity instruments across global markets
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Analyst Recommendations Analyst recommendations and target price estimates broken down by several categories
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	ETF Directory Find actively traded Exchange Traded Funds (ETF) from around the world
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings

Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.84)

Revenue Per Share

8.353

Quarterly Revenue Growth

0.091

Return On Assets

(0.0247)

Return On Equity

(0.08)

The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine AngioDynamics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

AngioDynamics Financials

AngioDynamics Most Recent Estimates

Cash and Equivalents

48.65 Million

Chance Of Distress

Less than 3

AngioDynamics Company Summary

AngioDynamics Key Financial Ratios

AngioDynamics Key Balance Sheet Accounts

AngioDynamics Key Income Statement Accounts

AngioDynamics Key Cash Accounts

AngioDynamics Financial Ratios Relationships

AngioDynamics Systematic Risk

About AngioDynamics Financials

Steps to analyze AngioDynamics Financials for Investing

AngioDynamics Thematic Clasifications

AngioDynamics March 23, 2023 Opportunity Range

Complementary Tools for AngioDynamics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY